bioAffinity Technologies, Inc. (BIAF)
Automate Your Wheel Strategy on BIAF
With Tiblio's Option Bot, you can configure your own wheel strategy including BIAF - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BIAF
- Rev/Share 0.5419
- Book/Share 0.0885
- PB 2.7672
- Debt/Equity 0.9248
- CurrentRatio 0.5457
- ROIC -3.4754
- MktCap 6972588.0
- FreeCF/Share -0.409
- PFCF -1.0487
- PE -0.409
- Debt/Assets 0.24
- DivYield 0
- ROE -3.6764
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
Published: June 26, 2025 by: Business Wire
Sentiment: Neutral
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity scientists present breakthrough research on using siRNAs to knock down two receptors on the cell membrane to selectively kill cancer cells.
Read More
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Negative
bioAffinity's first-quarter 2025 results show CyPath Lung sales growth and cost cuts despite a drop in total revenues and a wider quarterly net loss.
Read More
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral
JERSEY CITY, N.J. , May 7, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other estimated expenses payable by the company.
Read More
bioAffinity Technologies Announces Closing of $3.25 Million Offering
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today closed the previously announced best efforts offering of securities for aggregate gross proceeds of $3.25 million.
Read More
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
Published: April 17, 2025 by: Business Wire
Sentiment: Neutral
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies is implementing efficiency measures for CyPath Lung that streamline lab processing and data acquisition and reduce lab costs.
Read More
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
bioAffinity witnesses record 2024 revenues, driven by CyPath Lung adoption, Medicare coverage and strategic expansion across healthcare networks.
Read More
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
Published: February 25, 2025 by: Business Wire
Sentiment: Neutral
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity has entered into warrant exercise agreements to exercise certain outstanding warrants for gross cash proceeds of $1.4 million.
Read More
About bioAffinity Technologies, Inc. (BIAF)
- IPO Date 2022-09-01
- Website https://www.bioaffinitytech.com
- Industry Medical - Diagnostics & Research
- CEO Maria Zannes
- Employees 57